Search | IOVS | ARVO Journals

View

Showing 1 – 6 of 6

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

M-CHARTS evaluation and comparison of two Aflibercept regimens for neovascular age-related macular degeneration

Marion Schroeder; Monica K Loevestam-Adrian

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):306. doi:

ARVO Annual Meeting Abstract June 2020

Electrophysiological and morphological evaluation during 18 months follow-up of two regimens using Aflibercept for neovascular age-related macular degeneration (nAMD).

Marion Schroeder; Ulrika Kjellstrom; Monica Karin Loevestam-Adrian

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2641. doi:

ARVO Annual Meeting Abstract July 2019

Twelve percent of 6142 patients treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within two years. Analysis from the Swedish Macula Registry (SMR).

Marion Schroeder; Monica Karin Loevestam-Adrian

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):91. doi:

ARVO Annual Meeting Abstract July 2018

Vertical metamorphopsia improved in patients treated with Aflibercept for neovascular AMD at eighteen months follow-up.

Marion Schroeder; Monica Loevestam-Adrian

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2379. doi:

ARVO Annual Meeting Abstract June 2017

Retinal function improved, assessed with 30-HZ flicker, in patients treated with Aflibercept for neovascular AMD at six months follow-up.

Marion Schroeder; Ivana Huzevkova; Sten Andreasson; Monica Loevestam-Adrian

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):872. doi:

ARVO Annual Meeting Abstract September 2016

No improvement in visual outcome over time in two cohorts from the same county in patients treated for wet AMD.

Marion Schroeder; Lena Rung; Monica K Lovestam Adrian

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3359. doi:

Advertisement